scholarly journals Application of the International Society on Thrombosis and Haemostasis Scoring System in Evaluation of Disseminated Intravascular Coagulation in Patients with Acute Leukemias

Author(s):  
Aditi Aggarwal ◽  
Deepti Mahajan ◽  
Poonam Sharma

Abstract Background Coagulation abnormalities are common in acute leukemia (AL) and disseminated intravascular coagulation (DIC) frequently complicates the onset of AL. Aim To determine the prevalence of overt DIC in AL using the International Society on Thrombosis and Haemostasis (ISTH) scoring system. Materials and Methods This prospective observational study was performed on 57 newly diagnosed or relapsed cases of AL. Detailed clinical history and coagulation profile of the patients were evaluated. Diagnosis of overt and nonovert DIC was established using the ISTH scoring system and results tabulated. Observations A total of 57 patients with AL participated in the study, including 31 (54.39%) patients with acute lymphoblastic leukemia (ALL) and 26 (45.61%) with acute myeloid leukemia (AML). In total, 18 of 57 patients (31.58%) with AL fulfilled the criteria of overt DIC according to the ISTH scoring system, including 10 (32.25%) patients with ALL and 8 (30.76%) patients with AML. The highest prevalence of DIC was seen in the M3 subtype among AML and the L1 subtype among ALL, respectively. The mean ISTH score in patients of overt DIC in ALL and AML patients was 5.1 and 5, respectively. Abnormalities in platelet count and D-dimer levels were the most useful parameters in diagnosing overt DIC and the difference between overt DIC and nonovert DIC groups was highly significant. Conclusions Overt DIC was observed in approximately one-third of patients with AL. Prevalence of overt DIC was found to be comparable in patients with ALL and AML. Mean platelet count and D-dimer levels were the most useful parameters in detecting overt DIC.

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1412-1412
Author(s):  
Priya Patel ◽  
Amanda Walborn ◽  
Debra Hoppensteadt ◽  
Michael Mosier ◽  
Matthew T. Rondina ◽  
...  

Abstract Introduction: Sepsis is a severe systemic inflammatory response to infection that manifests with widespread inflammation as well as endothelial and coagulation dysfunction that may lead to hypotension, organ failure, shock, and death. Disseminated intravascular coagulation (DIC) is a complication of sepsis involving systemic activation of the fibrinolytic and coagulation pathways that can lead to multi-organ dysfunction, thrombosis, and bleeding, with a two-fold increase in mortality. Elevated levels of nucleosomes released from apoptotic cells have been detected in the blood of severe sepsis patients. Procalcitonin (PCT), a propeptide of calcitonin, is a marker of inflammation of infectious origins. Both nucleosomes and PCT are associated with the inflammatory and infectious processes that play a key role in the pathogenesis of sepsis and DIC. No single biomarker or laboratory test can effectively diagnose DIC; accordingly, the International Society on Thrombosis and Hemostasis (ISTH) has developed a diagnostic algorithm based on clinical parameters that uses platelet count, prothrombin time (PT), fibrin related marker (D-dimer) and fibrinogen levels to calculate a DIC score. This study lays the groundwork for the development of a diagnostic algorithm using several markers of inflammation and infection and DIC score as parameters in assessing severity of sepsis-associated coagulopathy (SAC) in a clinical setting. Materials and Methods: De-identified serial plasma samples from patients diagnosed with sepsis-associated coagulopathy (n=137) were obtained from the University of Utah under an IRB approved protocol. The citrated plasma samples were collected from adult patients in the ICU upon admission and ICU days 4 and 8 In addition, plasma samples from healthy volunteers (n=50) were purchased from George King Biomedical (Overland, KS). Platelet count, prothrombin time, International normalized ratio (INR), D-dimer and fibrinogen levels were used to assign International Society of Thrombosis and Hemostasis (ISTH) DIC scores. Plasma samples were analyzed for procalcitonin (PCT) (Abcam, Cambridge, MA) and extracellular nucleosomes (Roche Diagnostics, Indianapolis, IN)) using a commercially available ELISA methods. In addition, markers of inflammation including interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10) and tumor necrosis factor α (TNF α) were measure using the Biochip Array from Randox (Crumlin, County Antrim, UK). Results: DIC scores were calculated using the ISTH criteria and categorized into sepsis without DIC, non-overt DIC, and overt DIC. The levels of PCT were elevated in all three groups compared to normal (p<0.05). In addition, the patients with overt DIC had a higher level of PCT on day 0 and 4, compared to patients with non-overt DIC or sepsis alone. On day 8, the overt and non-overt DIC patients had similar levels of PCT. PCT data is shown in Table 1 (mean ± SEM). Nucleosome levels were also measured and compared between groups. Similarly, markers of inflammation, including IL-6, IL-8, IL-10 and TNF α were higher in the overt DIC group compared to the other groups on day 0 and day 4. By day 8, most of the patients initially diagnosed with overt DIC had transitioned into the non-overt group or died prior to the blood draw. The PCT levels correlated with nucleosomes, IL-6, IL-8, IL-10 and TNF α levels (p<0.05, Spearman r>0.20). Conclusions: This study demonstrates the diagnostic and prognostic value of profiling several biomarkers of inflammation and infection in patients with sepsis-associated DIC to assess the severity of illness. Elevated levels of PCT, IL-6, IL-8, IL-10 and TNF-α were observed in most patients with sepsis and DIC. Additionally, the levels of these markers show significant positive correlations to each other and to DIC score. Currently, no single biomarker can be used to confirm the diagnosis of DIC in patients with sepsis. This study provides an initial framework in developing a multiparametric profile of biomarkers in DIC for diagnostic and prognostic purposes. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
Vol 8 (02) ◽  
pp. 85-90
Author(s):  
Shivakumarswamy Udasimath ◽  
Nagesha K.R ◽  
Kumar Naik H.K. ◽  
Puruhotham R

BACKGROUND Throughout the world, millions of people are affected by corona virus disease 2019 (Covid-19). 16 % of infected Covid-19 people may need hospitalisation. Patients with severe respiratory or systemic manifestations are at increased risk of venous thromboembolism. Thrombocytopenia, elevated D-Dimer, prolonged prothrombin time, and features of disseminated intravascular coagulation laboratory findings are included in initial reports on Covid-19 patients’ blood samples. METHODS This cross-sectional study was conducted at pathology laboratory, Hassan Institute of Medical Sciences, Hassan, between June 01, 2020 to August 29, 2020. 4096 patients’ blood samples with Covid-19 positivity in Covid Hospital of Hassan Institute of Medical Sciences, Hassan, were analysed in detail and statistical reports were derived from the fresh samples for platelet count, prothrombin time and D-Dimer. The results were compared with severity of infection. RESULTS Analysis of 4096 Covid-19 blood sample results, revealed significant abnormal mean values in critical cases for platelet count in which it was severely decreased (35,000 cells / cumm), prothrombin time was prolonged for more than 180 seconds and D-Dimer values were 3.74 microgram per ml. CONCLUSIONS As the pandemic is spreading, we highlight the importance of laboratory and clinical findings of coagulation disorders in Covid-19 infected patients. To prevent death of Covid-19 infected patients, noticing the laboratory findings related to coagulation will help in early detection of critical patients. This is very important for relevant treatment and may prevent mortality in Covid-19 infected patients. KEYWORDS Coagulation, Coronavirus, Venous Thromboembolism (VTE), Prothrombin Time, Disseminated intravascular coagulation (DIC)


2021 ◽  
Vol 41 (02) ◽  
pp. 120-126
Author(s):  
Hugo ten Cate ◽  
Avi Leader

AbstractDisseminated intravascular coagulation (DIC) is characterized by the intravascular activation of coagulation with loss of localization arising from different causes, and is diagnosed using scoring systems which rely upon the presence of an underlying disorder compatible with DIC alongside hemostatic derangements such as low platelet count, prolonged prothrombin time, and elevated fibrinogen degradation products. DIC is common in patients with acute leukemia, with prevalence ranging from 17 to 100% in acute promyelocytic leukemia (APL) and 8.5 to 25% in acute lymphoblastic leukemia (ALL) and non-APL acute myeloid leukemia (AML). The pathophysiology is complex and varies between the leukemia subtypes, and is not fully reflected by the laboratory markers currently used to classify DIC. Similarly, the clinical consequence of DIC in acute leukemia also varies across the types of leukemia. DIC is primarily associated with bleeding in APL, while thrombosis is the dominant phenotype in ALL and non-APL AML. The cornerstone of managing DIC is the treatment of the underlying disease, as exemplified by the important role of early administration of all-trans retinoic acid in APL. Other aspects of management focus on supportive care aimed at minimizing the risk of bleeding, via transfusion of blood products. The use of blood products is more liberal in APL, due to the hemorrhagic phenotype and unacceptably high rates of early hemorrhagic death. This review will focus on the pathophysiology, risk factors, clinical implications, and the management of DIC in patients across the spectrum of acute leukemias.


Sign in / Sign up

Export Citation Format

Share Document